This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to
characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID
continuously in 28-day cycles in both study parts.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03028103
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
All locations for NCT03028103
United States (3)
University of Arizona Cancer Center
Tucson, Arizona, United States, 85719
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Columbia University Medical Center
New York, New York, United States, 10032
View full eligibility
Tris trial is registered with FDA with number: NCT03028103. The sponsor of the trial is Epizyme, Inc. and it is looking for 28 volunteers for the current phase.
Official trial title: An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!